Author (year) | N° of patients | Study design | Histology | RTx | CTx regime | Median OS in months | Local failure rate | pCR rate | Hemato-logic toxicity (≥ III°) |
---|---|---|---|---|---|---|---|---|---|
Bates [8] (1996) | 35 | Phase 2 | 80% SCC | 45 Gy (25 Fx) | Cisplatin 5FU | 25.8 | 7% | 51% | 17% |
Tepper [2] (2008) | 30 (trimodal therapy) | Phase 3 | 23% SCC | 50.4 Gy (28 Fx) | Cisplatin 5FU | 53.8 | 13% | 40% | 57% |
Bosset [18] (1997) | 143 (trimodal therapy) | Phase 3 | 100% SCC | 18.5 Gy (5 Fx) | Cisplatin (0–2 days before first day of radiotherapy) | 18.6 | – | 26% | – |
178 (trimodal therapy) | Phase 3 | 23% SCC | 41.4 Gy (23 Fx) | Carboplatin Paclitaxel | 48.6 (all) 81.6 (SCC) | 22% | 29% (all) 49% (SCC) | 8% | |
Bedenne [11] (2007) | 129 (trimodal therapy) | Phase 3 | 89% SCC | 46 Gy (23 Fx) or 15 Gy (5 Fx) – week 1 + 4 | Cisplatin 5-Fluoruracil | 17.7 | 33.6% | – | – |
Urba [19] (2003) | 69 | Phase 2 | 14% SCC | 45 Gy (30 Fx) – twice daily | Cisplatin Paclitaxel | 24 | – | 22% | 13%a |
Blom [4] (2014) | 165 | Retro-spective analysis | 24% SCC | 1. 50.4 Gy (28 Fx) 2. 41.4 Gy (23 Fx) | 1. Cisplatin 5-Fluoruracil 2. Carboplatin Paclitaxel | Not reached after 3 years | – | 38% 24% | 1.15%a 2.2% a |
van Meerten [14] (2006) | 54 | Phase 2 | 22% SCC | 41.4 Gy (23 Fx) | Carboplatin Pacliataxel | Not reached after median follow up of 31 months | 13% | 25% | 25% a |
This analysis | 51 | Retro-spective analysis | 100% SCC | 1. 45 Gy (25 Fx) 2. 41.4 Gy (23 Fx) | 1. Cisplatin 5-Fluoruracil 2. Carboplatin Paclitaxel | 1. 40.1 2. 23.9 | 1. 34% 2. 21% | 1. 38% 2. 26% | 1. 58% 2. 20% |